Truist analyst Srikripa Devarakonda downgraded Tourmaline Bio (TRML) to Hold from Buy with a price target of $48, down from $63, Following the announcement of Novartis’ (NVS) planned acquisition of Tourmaline.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- Tourmaline Bio downgraded to Hold from Buy at Jefferies
- Nebius enters AI pact with Microsoft, Teck to combine with Anglo: Morning Buzz
- Tourmaline Bio downgraded to Market Perform from Outperform at LifeSci Capital
- Hold Rating Maintained Amidst Novartis’s Strategic Acquisition of Tourmaline Bio: Balancing Opportunities and Risks
- Tourmaline Bio downgraded to Neutral from Buy at Guggenheim